Summary
TransDigm Group Incorporated (TDG) announced the completion of its acquisition of Harco Laboratories, Incorporated on December 9, 2011. This acquisition, previously announced on November 8, 2011, was executed for approximately $84 million in cash. This event is significant for investors as it represents a strategic move to expand TransDigm's business. The filing details the completion of this transaction, underscoring the company's ongoing strategy of growth through acquisitions. Investors should look for subsequent filings to understand the financial impact and integration of Harco Laboratories into TransDigm's operations.
Key Highlights
- 1TransDigm Group Incorporated completed the acquisition of Harco Laboratories, Incorporated on December 9, 2011.
- 2The acquisition cost was approximately $84 million in cash.
- 3The transaction was previously announced on November 8, 2011.
- 4This 8-K filing primarily serves as a Regulation FD disclosure regarding the acquisition's completion.
- 5Exhibit 99.1, a press release announcing the acquisition, is attached to the filing.
Frequently Asked Questions
The primary purpose of this Form 8-K filing was to disclose the completion of TransDigm Group Incorporated's acquisition of Harco Laboratories, Incorporated, in accordance with Regulation FD.
The acquisition of Harco Laboratories cost approximately $84 million in cash. While this filing confirms the completion, investors will need to refer to future financial reports for a detailed analysis of the acquisition's financial impact on TransDigm's revenue, profitability, and balance sheet.
The acquisition of Harco Laboratories was first announced by TransDigm Group Incorporated on November 8, 2011.
No, this specific Form 8-K filing does not include detailed financial statements for the acquired entity or pro forma financial information. It primarily serves as a disclosure of the event's completion and attaches the press release.